Home › Funds › Enavate Sciences GP, LLC › UPB
Enavate Sciences GP, LLC position in UPB
UPSTREAM BIO INC · Health Care
Enavate Sciences GP, LLC reported holding 2,459,703 shares of UPB (UPSTREAM BIO INC) in its Q2 2026 13F filing — a position valued at US$17.0M, representing 4.93% of its reported portfolio and ranking #6 among its reported holdings. Enavate Sciences GP, LLC has disclosed UPB holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Enavate Sciences GP, LLC's UPB position evolved
Enavate Sciences GP, LLC first disclosed a stake in UPB in Q4 2024 at 2,459,703 shares (US$40.4M). The position peaked in Q4 2025 at 2,459,703 shares, worth US$66.8M. Across 7 filings, Enavate Sciences GP, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,459,703 shares valued at US$17.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 2.46M | $40.44M | New |
| Q1 2025 | 2.46M | $15.05M | Hold |
| Q2 2025 | 2.46M | $27.01M | Hold |
| Q3 2025 | 2.46M | $46.27M | Hold |
| Q4 2025 | 2.46M | $66.78M | Hold |
| Q1 2026 | 2.46M | $22.14M | Hold |
| Q2 2026 | 2.46M | $17.02M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About UPB and 13F data
UPB (UPSTREAM BIO INC) is a Health Care company. 56 other funds we track also report a position in UPB — the largest reported positions include ORBIMED ADVISORS LLC (US$39.4M), Decheng Capital LLC (US$18.9M), Parkman Healthcare Partners LLC (US$6.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding UPB
- ORBIMED ADVISORS LLC 5.69M sh · $39.40M · Q2 2026
- Decheng Capital LLC 2.72M sh · $18.86M · Q2 2026
- Parkman Healthcare Partners LLC 935.25K sh · $6.47M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 600.95K sh · $4.16M · Q2 2026
- Samsara BioCapital, LLC 353.72K sh · $2.45M · Q2 2026
- Propel Bio Management, LLC 350.39K sh · $2.42M · Q2 2026
More on Enavate Sciences GP, LLC
FAQ
How long has Enavate Sciences GP, LLC held UPB?
Enavate Sciences GP, LLC has disclosed UPB holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Enavate Sciences GP, LLC's current position in UPB?
As of Q2 2026, Enavate Sciences GP, LLC holds 2.46M shares of UPB (UPSTREAM BIO INC), valued at $17.02M, representing 4.93% of its reported portfolio and ranking #6.
Has Enavate Sciences GP, LLC been buying or selling UPB?
In the latest 13F filing (Q2 2026), Enavate Sciences GP, LLC held unchanged its position in UPB. The position peaked in Q4 2025 at 2.46M shares.
Which other funds hold UPB?
Other major institutional holders of UPB include ORBIMED ADVISORS LLC, Decheng Capital LLC, Parkman Healthcare Partners LLC, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.